Perspective Therapeutics to Participate in Upcoming Investor Conferences
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced its senior leadership team will participate in two upcoming investor conferences: the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, and the Piper Sandler Spring Biopharma Symposium in Boston on April 16, 2026. The company, a radiopharmaceutical developer, will be available for one-on-one meetings with investors at these virtual and in-person events. Perspective Therapeutics is advancing treatments for various cancers using an alpha-emitting isotope and a "theranostic" approach.
Perspective Therapeutics lines up Needham, Piper investor meetings
Perspective Therapeutics (NYSE AMERICAN: CATX) announced that its senior leadership will participate in investor events in April 2026. This includes a presentation and fireside chat at the Needham Virtual Healthcare Conference on April 14, 2026, and one-on-one meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026, in Boston. The company, a radiopharmaceutical development firm, will discuss its advanced treatments for cancers and corporate strategy.
Perspective Therapeutics to Participate in Upcoming Investor Conferences
Perspective Therapeutics, Inc. announced that its senior leadership will attend two upcoming investor conferences in April 2026. The company will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14th and the Piper Sandler Spring Biopharma Symposium on April 16th for one-on-one meetings. Perspective Therapeutics is a radiopharmaceutical development company focused on advanced cancer treatments using its proprietary alpha-emitting isotope 212 Pb technology.
Perspective Therapeutics to Participate in Upcoming Investor Conferences
Perspective Therapeutics, a radiopharmaceutical development company, announced its senior leadership team will participate in two upcoming investor conferences: the 25th Annual Needham Virtual Healthcare Conference on April 8, 2026, and the Piper Sandler Spring Biopharma Symposium on April 16, 2026. The company will be available for one-on-one meetings at both events, with a presentation and fireside chat scheduled for the Needham conference. Perspective Therapeutics specializes in advanced treatments for cancer using alpha-emitting isotope 212Pb.
Perspective Therapeutics to Participate in Upcoming Investor Conferences
Perspective Therapeutics announced that its senior leadership team will participate in two upcoming investor conferences: the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, and the Piper Sandler Spring Biopharma Symposium on April 16, 2026. The company is a radiopharmaceutical development firm focusing on advanced cancer treatments using the alpha-emitting isotope 212 Pb. They are currently conducting Phase 1/2a imaging and therapy trials for neuroendocrine tumors, melanoma, and solid tumors, utilizing a theranostic approach.
Perspective Therapeutics updates corporate presentation, expects Phase 1/2 data across three programs in 2026
Perspective Therapeutics (CATX) has updated its corporate presentation, indicating expectations for Phase 1/2 data readouts across all three of its clinical programs in 2026. The company is advancing a wholly owned 212Pb-based radiopharmaceutical portfolio for solid tumors, with one program, VMT-α-NET, showing compelling anti-tumor activity. Two other programs, VMT01 and PSV359, are in ongoing Phase 1/2a trials, with PSV359 reporting improved tumor retention.
Perspective Therapeutics (NYSE: CATX) spotlights 212Pb radiopharmaceutical cancer pipeline
Perspective Therapeutics (NYSE: CATX) has updated its corporate presentation, highlighting its focus on a proprietary lead-212 (212Pb) radioligand platform for next-generation radiopharmaceutical cancer therapies. The presentation details a wholly owned 212Pb-based oncology portfolio, including VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors. Early Phase 1/2a trials show promising anti-tumor activity and favorable tolerability, with Phase 1/2 data across all three programs anticipated in 2026.
Perspective Therapeutics Q1 EPS Raised by HC Wainwright
HC Wainwright has increased its Q1 2026 EPS estimate for Perspective Therapeutics (NYSEAMERICAN:CATX) from ($0.38) to ($0.30), reiterating a "Buy" rating and a $13.00 price target. This adjustment follows the company's Q1 report of ($0.51) EPS on $0.04 million in revenue, which included significant negative margins. Despite recent poor financial performance, the stock holds a consensus "Buy" rating from analysts with an average target price of $12.63 and institutional ownership around 54.7%.
H.C. Wainwright raises Perspective Therapeutics price target to $13
H.C. Wainwright has increased its price target for Perspective Therapeutics Inc (NYSE:CATX) to $13 from $12, maintaining a Buy rating. This adjustment comes despite the company reporting a wider net loss for 2025 than previously estimated, with H.C. Wainwright projecting a narrower net loss for 2026. The firm highlighted Perspective Therapeutics' strong cash position, providing an operational runway into late 2027, and noted other analysts' varied but generally positive outlooks.
H.C. Wainwright raises Perspective Therapeutics price target to $13
H.C. Wainwright has increased its price target for Perspective Therapeutics Inc (NYSE:CATX) to $13 from $12, maintaining a Buy rating. This adjustment follows the company's Q4 2025 financial results, which included a wider net loss than anticipated but also a stronger projected net loss for 2026 and a significant cash runway into late 2027 due to recent equity financing. Other analyst firms like RBC Capital, Jones Trading, Truist Securities, BTIG, and Oppenheimer also provided updated ratings and price targets, reflecting varied but generally positive interest in the company's clinical pipeline and financial health.
CATX: HC Wainwright & Co. Raises Price Target to $13, Maintains Buy Rating | CATX Stock News
HC Wainwright & Co. has raised its price target for Perspective Therapeutics (CATX) to $13 from $12, while maintaining a Buy rating, indicating continued positive outlook for the stock. This follows several other analysts reiterating Buy or Outperform ratings with adjusted price targets. Perspective Therapeutics, Inc. focuses on radiopharmaceutical development using Lead-212 (212Pb) to target cancer cells.
Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $13.00 Price Target at HC Wainwright
HC Wainwright has increased its price target for Perspective Therapeutics (NYSEAMERICAN:CATX) to $13.00, up from $12.00, while reiterating a "buy" rating. This new target implies a potential upside of approximately 192.13% from the current stock price. Despite the company reporting a loss and minimal revenue in its last quarter, analyst consensus remains largely positive, with an average price target of $12.63 across various firms.
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index
Perspective Therapeutics, Inc. (NYSEAM:CATX) has been included in the S&P Biotechnology Select Industry Index. This news follows a series of recent adjustments to analyst price targets and coverage initiations for the company, indicating increased attention and activity around its stock. The company specializes in developing radiopharmaceutical treatments for cancer, utilizing alpha-emitting isotopes for targeted therapy and diagnostic imaging.
If You Invested $1,000 in Perspective Therapeutics Inc (CATX)
This article analyzes the historical performance of a $1,000 investment in Perspective Therapeutics Inc (CATX) over different periods, comparing it against the S&P 500. It details the company's focus as a radiopharmaceutical development company specializing in targeted alpha-emitting isotope Lead-212 (212Pb) for cancer treatments, including key clinical programs and manufacturing capabilities. While a $1,000 investment a year ago would have yielded a substantial return, longer-term investments (5 and 10 years) show significant losses.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Buy" from Analysts
Nine analysts have issued a "Buy" consensus recommendation for Perspective Therapeutics, Inc. (CATX), with an average one-year price target of $12.50. Despite this bullish outlook, the company’s stock opened down around 3.3% at $4.45, and it continues to face operating losses with a recent quarterly EPS of ($0.51) on minimal revenue. Perspective Therapeutics is focused on developing precision-targeted alpha therapies, with lead candidates VMT-a-NET and VMT01 currently undergoing Phase 1/2a clinical trials for various cancer types.
Perspective Therapeutics (CATX) Receives Analyst Rating Boost
B. Riley Securities has maintained a 'Buy' rating for Perspective Therapeutics (CATX) and increased its price target from $11.00 to $13.00, reflecting an 18.18% boost. This update comes amidst other recent analyst ratings, including a reiterated 'Buy' from BTIG and an 'Outperform' initiation by Piper Sandler. Perspective Therapeutics, a radiopharmaceutical company, focuses on developing advanced cancer treatments using its proprietary Lead-212 isotope technology.
Perspective Therapeutics Q1 EPS Boosted by Brookline Cap M
Brookline Cap M has increased its Q1 2026 EPS estimate for Perspective Therapeutics (CATX) to ($0.31) from ($0.44), forecasting a full-year EPS of ($1.27). Despite reporting a Q1 EPS of ($0.51) and negative financial metrics, sell-side analysts maintain a "Buy" consensus with an average price target of $12.50. Institutional ownership stands at approximately 54.66%, and the company has received multiple price target raises and reaffirmations of "Buy" ratings from various firms.
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX)
Three analysts have issued bullish sentiments on several healthcare stocks, including Lantheus (LNTH), Perspective Therapeutics (CATX), and Monte Rosa Therapeutics (GLUE). Lantheus received a maintained Buy rating from William Blair with a strong buy consensus, while Perspective Therapeutics also maintained a Buy rating from LifeSci Capital with significant upside potential. Monte Rosa Therapeutics maintained a Buy rating from TD Cowen, also showing a strong buy consensus from the street.
Jones Trading reiterates Perspective Therapeutics stock Buy rating
Jones Trading reiterated a Buy rating and an $18.00 price target for Perspective Therapeutics (NYSE:CATX), following the company's fiscal 2025 earnings and a management call, citing strong optimism for its Pb-212-VMT-α-NET trial. Other analysts, including RBC Capital, Truist Securities, BTIG, Oppenheimer, and Piper Sandler, have also provided ratings and price targets, reflecting varying perspectives on the company's recent performance and future potential, especially concerning its lead-212 radiotherapies. The company expects "meaningful regulatory engagement in 2026" based on advancing clinical data, with the next clinical readout anticipated at the American Association for Cancer Research Annual Meeting.
UBS Group Forecasts Strong Price Appreciation for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock
UBS Group has raised its price target for Perspective Therapeutics (NYSEAMERICAN:CATX) to $8.00 from $7.00, maintaining a "buy" rating and suggesting a significant upside. Despite weak fundamentals, the company shows positive clinical progress with promising data for its [212Pb]VMT‑α‑NET therapy. Institutional investors have also been adjusting their holdings in the company.
Perspective Therapeutics (CATX) Rating Reiterated by Wedbush | C
Wedbush has reiterated its "Outperform" rating for Perspective Therapeutics (CATX), maintaining a price target of $11.00 USD. This follows a series of analyst updates, including BTIG's "Buy" rating and RBC Capital's "Outperform" rating with a revised price target. Perspective Therapeutics, a radiopharmaceutical company, is developing advanced cancer treatments using the alpha-emitting isotope Lead-212 (212Pb).
Perspective Therapeutics (NYSEAMERICAN:CATX) Receives Outperform Rating from Wedbush
Wedbush reissued an "Outperform" rating for Perspective Therapeutics (CATX) with an $11 price target, indicating a potential 122% upside, and the stock holds a consensus "Buy" rating among analysts. Despite positive clinical catalyst from updated VMT-α-NET data showing encouraging anti-tumor activity and no serious toxicities, the company faces material operating risks with a reported quarterly loss of ($0.51) EPS on low revenue, highlighting ongoing cash burn. Institutional investors have been actively trading CATX shares, with Patient Square Capital LP and Avidity Partners Management LP among those adjusting their stakes.
B. Riley Raises Price Target on Perspective Therapeutics to $13 From $11, Keeps Buy Rating
B. Riley has increased its price target for Perspective Therapeutics from $11 to $13, while maintaining a Buy rating on the company's stock. This adjustment reflects an updated outlook from the analyst firm. Perspective Therapeutics, a radiopharmaceutical development company, focuses on advanced treatment applications for cancers using proprietary alpha-emitting isotope technology.
Oppenheimer reiterates Perspective Therapeutics stock rating at Outperform
Oppenheimer reaffirmed its Outperform rating and $13.00 price target for Perspective Therapeutics (NYSE: CATX) after the company reported its full-year 2025 results. Despite the stock appearing overvalued according to InvestingPro, the company showed progress in its clinical trials and extended its cash runway into late 2027 with a recent $164 million raise. Other analysts, including Piper Sandler and H.C. Wainwright, have also issued positive ratings and price targets, particularly noting the company's lead-212 radiotherapies following a competitor's deprioritization of a similar agent.
Perspective Therapeutics (CATX) to Release Earnings on Wednesday
Perspective Therapeutics (CATX) is set to release its Q4 2025 earnings on Wednesday, March 25th, with analysts anticipating an EPS of ($0.36) and revenue of $0.232 million. Despite continued operating losses and financing risks, the company has promising clinical data for its lead radiopharmaceutical and has seen recent insider purchases indicating management confidence. Analysts generally hold a "Buy" rating with an average price target of $12.13, even as the stock recently traded down 5.2% to $4.95.
Perspective Therapeutics to share tumor therapy data at 2026 cancer meeting
Perspective Therapeutics (CATX) announced that updated data for its [212Pb]VMT-α-NET program, targeting advanced SSTR2+ neuroendocrine tumors, has been accepted for a poster presentation at the AACR Annual Meeting 2026. The presentation, scheduled for April 20, 2026, will report on safety and preliminary efficacy from dose-finding cohorts 1–3. This continues the company's pattern of providing recurring visibility for the VMT-α-NET program through various clinical and corporate milestones.
Perspective Therapeutics Announces Acceptance of VMT-α-NET
Perspective Therapeutics announced that updated data for its [212Pb]VMT-α-NET program, designed to treat SSTR2+ neuroendocrine tumors, has been accepted for a poster presentation at the AACR Annual Meeting 2026. The presentation will detail safety and preliminary efficacy results from the dose-finding cohorts. Previously reported interim analysis from ASCO-GI showed a favorable tolerability profile and anti-tumor activity in treated patients, with no dose-limiting toxicities.
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
Perspective Therapeutics announced that updated data on its [212Pb]VMT-α-NET program have been accepted for a poster presentation at the AACR Annual Meeting 2026. The presentation will detail safety and preliminary efficacy results from dose-finding cohorts in patients with SSTR2+ neuroendocrine tumors. The data, including safety findings from 56 patients, showed no dose-limiting toxicities, treatment-related discontinuations, or serious renal complications, with anti-tumor activity observed in a significant portion of patients.
Perspective Therapeutics Announces Acceptance of VMT-α-NET
Perspective Therapeutics announced that updated data on its [212Pb]VMT-α-NET program have been accepted for a poster presentation at the AACR Annual Meeting 2026. This data includes safety and preliminary efficacy results from dose-finding cohorts in patients with SSTR2+ neuroendocrine tumors. The company previously reported interim analysis at the 2026 ASCO Gastrointestinal Cancers Symposium, highlighting a favorable tolerability profile and evidence of anti-tumor activity for VMT-α-NET.
Royal Bank Of Canada Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $14.00
Royal Bank of Canada has reduced its price target for Perspective Therapeutics (NYSEAMERICAN:CATX) from $18.00 to $14.00, while maintaining an "outperform" rating, indicating a potential upside of 181.86%. Despite weak fundamentals and negative earnings per share, the stock holds an average "Buy" rating from analysts with an average target price of $12.13. Institutional investors also show significant holdings in the company.
Truist reiterates Buy on Perspective Therapeutics stock
Truist Securities has reiterated a Buy rating and a $12.00 price target on Perspective Therapeutics Inc (NYSE:CATX). The firm expects important Cohort 2 data for VMT-α-NET by mid-2026, viewing this as a key milestone for the program in a market estimated at over $10 billion. Despite the stock's significant year-to-date surge and current trading at $5.22, Truist maintains its positive outlook, highlighting the potential of the 212-Pb alpha isotope and the company's strong cash position, though InvestingPro suggests it may be overvalued.
Perspective Therapeutics stock rating reiterated at Buy by BTIG
BTIG has reiterated a Buy rating and a $14 price target for Perspective Therapeutics Inc (NYSE:CATX) due to its consistent efficacy and safety profile demonstrated by VMT-α-NET, momentum from 2025 results, and Sanofi's deprioritization of a competing program. The company has significant data catalysts expected throughout 2026 and a strong cash position providing a runway into late 2027. While BTIG views shares as undervalued, InvestingPro's Fair Value analysis suggests potential overvaluation.
Perspective Therapeutics (NYSEAMERICAN:CATX) Receives "Buy" Rating from BTIG Research
BTIG Research has reiterated a "buy" rating for Perspective Therapeutics (NYSEAMERICAN:CATX), setting a price target of $14.00, which suggests a potential upside of 168.20%. Other analysts have also issued "buy" or "overweight" ratings for the stock, with an average target price of $12.38. The company recently reported its Q4 earnings with a negative EPS and revenue of $0.04 million; institutional investors and hedge funds own 54.66% of the stock.
Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 4.4% - Here's What Happened
Perspective Therapeutics (NYSEAMERICAN:CATX) saw its stock price rise by 4.4% on Monday, trading at $5.22 with a consensus "Buy" rating and an average target price of $12.38 from analysts. Despite weak current financials, the clinical-stage biotech company has several lead programs in Phase 1/2a trials, and institutional investors have recently increased their holdings.
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
Perspective Therapeutics, Inc. (CATX) provided recent business highlights and reported full year 2025 results, emphasizing the continued progress of its lead program VMT-α-NET for neuroendocrine tumors, which shows a favorable tolerability profile and durable disease control. The company also detailed the advancement of its other clinical programs, VMT01 and PSV359, and announced a cash position of approximately $145 million as of December 31, 2025, with an additional $164 million from a February 2026 equity offering. These funds are expected to support clinical milestones and operations into late 2027.
Perspective Therapeutics (NYSE: CATX) details 2025 loss and cash runway to 2027
Perspective Therapeutics reported a wider net loss of $103.1 million for 2025, an increase from $79.3 million in 2024, primarily due to a 102% surge in research and development expenses to $84.2 million. Despite increased operational costs and a $10.0 million non-cash impairment, the company secured approximately $164 million from a February 2026 equity offering, extending its cash runway into late 2027. This funding is critical for advancing its radiopharmaceutical programs, VMT-α-NET, VMT01, and PSV359, with significant clinical data readouts anticipated in 2026.
CATX: Clinical pipeline advances with strong safety, efficacy, and funding to support growth into 2027
Perspective Therapeutics, Inc. (CATX) has announced that its lead clinical programs show strong safety and efficacy signals. The company has secured significant funding through a major equity raise, extending its robust cash reserves to support milestones into late 2027, despite an increase in operating expenses and net loss year-over-year.
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
Perspective Therapeutics announced a business update and its full year 2025 financial results, highlighting progress in its radiopharmaceutical development programs. The company's lead program, VMT-α-NET for neuroendocrine tumors, continues to show favorable tolerability and disease control, with clinical updates across all programs anticipated throughout 2026. With approximately $145 million in cash and an additional $164 million from a recent equity offering, the company expects to fund operations and clinical milestones into late 2027.
Perspective Therapeutics Q4 2025 earnings preview
This article is a preview of Perspective Therapeutics' Q4 2025 earnings. It indicates that further details will be provided in the full article on MSN.
Perspective Therapeutics (CATX) Stock Forecast and Price Target 2026
Perspective Therapeutics (CATX) has a consensus "Buy" rating from 8 Wall Street analysts, with 7 buy ratings and 1 strong buy rating. The average twelve-month price target is set at $12.38, suggesting a significant upside of 143.60% from its current price of $5.08. Analysts have a positive outlook on CATX, favoring it over other "medical" companies.
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street analysts are expressing bullish sentiments on several healthcare stocks, including Perspective Therapeutics (CATX), Mesoblast (MESO), and Sagimet Biosciences, Inc. Class A (SGMT). Analysts have maintained "Buy" ratings and set price targets indicating significant upside potential for these companies. The article highlights specific analyst ratings and consensus price targets for each stock.
Perspective Therapeutics, Inc. Experiences Evaluation Revision Amidst Mixed Market Signals
Perspective Therapeutics, Inc., a microcap pharmaceutical and biotechnology company, has undergone an evaluation revision due to changing market conditions. The company has shown strong performance over the past year, significantly outperforming the S&P 500, with its stock currently at $5.10. Technical indicators offer a mixed outlook, showing both bullish and bearish signals across different timeframes, and while year-to-date returns are impressive, the company has faced longer-term challenges.
Director at Perspective Therapeutics (CATX) awarded 50,000 stock options for 2026
Perspective Therapeutics (CATX) director Lori A. Woods was granted 50,000 stock options as her annual equity award for 2026. The options have an exercise price of $5.35 per share and vest in full on March 2, 2027, provided she remains with the company. This transaction was reported via an SEC Form 4 filing.
Perspective Therapeutics (CATX) CEO receives 735,000-option 2026 equity grant
Perspective Therapeutics CEO Johan M. Spoor was granted 735,000 stock options as his annual 2026 equity award, approved by the board on January 26, 2026, with a grant date of March 2, 2026. These options will vest in 48 substantially equal monthly installments over four years, contingent on his continued service. The transaction was reported in an SEC Form 4 filing, indicating it was an equity award for compensation rather than an open-market purchase.
Director at Perspective Therapeutics (CATX) awarded 50K stock options
Robert F. Williamson III, a director at Perspective Therapeutics (CATX), reported receiving a grant of 50,000 stock options on March 2, 2026. This award, approved by the board on January 26, 2026, serves as his annual equity grant for the year. The options will fully vest on March 2, 2027, contingent upon his continued service to the company.
Perspective Therapeutics (CATX) CAO receives 90,000-stock-option equity award
Perspective Therapeutics' Chief Accounting Officer, Jonathan Robert Hunt, was granted 90,000 stock options as his annual equity award for 2026. These options have an exercise price of $0.0000 per share and will vest over four years in 48 equal monthly installments, contingent on his continued employment. This transaction was detailed in a Form 4 SEC filing, indicating it as a grant rather than an open-market trade.
Director at Perspective Therapeutics (CATX) awarded 50,000 stock options
Frank Morich, a director at Perspective Therapeutics (CATX), has been granted 50,000 stock options as his annual equity award for 2026. This grant was approved by the Board of Directors on January 26, 2026, with a grant date of March 2, 2026. The options will vest in full on March 2, 2027, provided Morich continues his service to the company.
CATX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Perspective Therapeutics Inc (CATX), including its income statement, balance sheet, and cash flow data derived from SEC filings. It highlights key financial metrics for fiscal year 2024, such as negative EBITDA and free cash flow, along with a low earnings quality ratio and a neutral Piotroski F-Score, suggesting reliance on accounting accruals rather than cash generation. The report also addresses frequently asked questions about the company's profitability, earnings per share, debt, and cash runway, indicating approximately 40 months of operating capacity at its current burn rate.
CATX SEC Filings - Perspective Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page provides access to Perspective Therapeutics Inc.'s (CATX) SEC filings, including 10-K, 10-Q, and 8-K forms, detailing financial conditions, clinical progress, and corporate governance. Stock Titan enhances this information with AI-powered summaries of key points from these regulatory disclosures. Recent significant filings include the appointment of a new CFO and director, stock option grants, and the company's Q2 2025 financial results.
Perspective Therapeutics (NASDAQ:CATX) Receives Average Recommendation of "Buy" from Brokerages
Seven research firms have issued an average "Buy" rating for Perspective Therapeutics (NASDAQ:CATX), with an average one-year price target of $11.86, suggesting significant upside from its recent open of $5.60. Analyst price targets vary, reflecting mixed expectations, but overall recommendations lean positive. Institutional investors hold approximately 54.7% of the company's stock, which has traded between $1.60 and $6.16 in the past year.
